Pharma boss smashes two glass ceilings
Inducted into the Hall of Fame as a "pioneer of breaking glass ceilings" in both gender and age, this pharma leader has been honoured for her vision and courage
Inducted into the Hall of Fame as a "pioneer of breaking glass ceilings" in both gender and age, this pharma leader has been honoured for her vision and courage
Healthtech has emerged as a major force in this year’s LinkedIn Top Startups Australia list, an annual ranking of the emerging companies where professionals want to work
This well-known boss is back in Australia and leading the region for a company that's chasing approvals globally for a drug that's been hailed a game-changer
Agreement brings together innovative anti-infective development platform and the Aussie giant's established regulatory, market access and commercial capabilities
UQ researchers selected to help the US produce personalised genetic therapies in hospitals to deliver RNA medicines to patients within days of diagnosis, instead of months
A lawsuit has been filed by investors who bought shares during a calamitous price plunge but CSL has promised to 'vigorously' defend all accusations
World-class facility in Melbourne will help deliver the next generation of life-changing treatments in cancer, heart disease, and neurological and autoinflammatory diseases
Funding CAR T treatments isn't enough when structural barriers prevent the majority of referrals from accessing CAR T.
Three flagship events brought together by AusBiotech for the first time is underway on the Gold Coast with more than 2500 expected to attend
An industry survey has uncovered the most important motivator for workplace engagement with more than 2300 open-ended comments pointing to one must-have
After a global search, CSL has picked a former Aussie GM and a 'world-class, purpose-driven' high-flyer from a rival pharma to be its fourth CEO
The more free meals a doctor receives from pharma, the more likely they are to prescribe less appropriate or more expensive drugs, according to a new review
An Australian company is helping time-poor doctors stay up to speed with the latest research by turning clinical papers into podcasts with pharmas on board as sponsors
This ASX-listed company has increased its stake to own two-thirds of a joint venture started two years ago but investors are not impressed
DHL has introduced advanced automation as part of a $9 million upgrade of its pharma facility in South-West Sydney
New website reveals that Australian patients are among the most active in the world when it comes to taking their case for medicines access to drug-pricing regulators
Among the 15-strong list are nine drugs vying to become the first to secure subsidy after being recommended at the PBAC's July 2026 meeting
The US President has come under scrutiny after boosting his pharma shareholdings by a breathtaking 3000 per cent last year. Find out which companies he's invested in and why it's caused controversy
One submission withdrawn, a couple of newcomers join the list and a potentially eye-opening DUSC analysis deferred as PBAC readies for its next meeting in a fortnight
The TGA has handed out eight orphan drug designations in the past quarter, with three of them targeting the same kidney disease.
The deal sees Roche take over late stage development and gain ex-China marketing rights for a range of ADCs.
Medicines Australia has named two high-profile company leaders as the newest additions to the Board, after Country Leadership changes mid-year resulted in departures
Two out of three companies hoping to cut a path to a broad listing were told the preliminary info they provided didn't cut it, according to outcomes from September's Intracycle Meeting
A high-profile former Senior Health Department official turned patient advocate has called on industry to force the Government to take HTA reform seriously by withholding all submissions from the PBAC
A second company has registered a copycat of a cancer drug across all tablet blister strengths, turning up the heat on the originator brand
A bitter court battle is heating up with two companies now accusing each other of misleading advertising over claims about side effects and speed of absorption
A report released by the ATO has revealed the total income declared in Australia for all pharmas who brought in at least a hundred million dollars. See the list
Product information updates for two jabs after reports of incorrect preparation and administration, which may result in the recall of patients for re-vaccination
Five companies have splashed cash on new assets to build out their current portfolios, with one hoping a Virtual Human AI platform will uncover transformative therapeutics
The PBAC has updated the guidelines for pharmas seeking multi-cancer listings, looking for information beyond the clinical